**Табела. 9.8** Компетентност ментора

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Име и презиме** | | | [Светлана Голочорбин Кон](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Golocorbin-Kon%20Svetlana&samoar=#.WUz16raxWUk) | | | | | | | | | |
| **Звање** | | | Ванредни професор | | | | | | | | | |
| **Ужа научна, уметничка односно стручна област** | | | Фармација | | | | | | | | | |
| **Академска каријера** | | Година | Институција | | | | Ужа научна, уметничка односно стручна област | | | | | |
| Избор у звање | | 2018. | Медицински факултет, Универзитет у Новом Саду | | | | Фармацеутска технологија са индустријском фармацијом и козметологијом | | | | | |
| Докторат | | 2009. | Технолошки факултет, Универзитет у Новом Саду | | | | Технологија фармацеутских производа - технологија | | | | | |
| Специјализација | | 2006. | Фармацеутски факултет, Универзитет у Београду | | | | Фармацеутска технологија | | | | | |
| Магистратура | | 2004. | Технолошки факултет, Универзитет у Новом Саду | | | | Технологија фармацеутских производа - технологија | | | | | |
| Диплома | | 1980. | Фармацеутски факултет, Универзитет у Београду | | | | Дипломирани фармацеут | | | | | |
| **Списак дисертација-докторских уметничких пројеката а у којима је наставнк ментор или је био ментор у претходних 10 година** | | | | | | | | | | | | |
| Р.Б. | Наслов дисертације- докторског уметничког пројекта | | | | Име кандидата | | | | \*пријављена | | \*\* одбрањена | |
| 1. | УТИЦАЈ ПОВИШЕНЕ ВЛАГЕ , ТЕМПЕРАТУРЕ И УЛТРАЉУБИЧАСТОГ ЗРАЧЕЊА НА СТАБИЛНОСТ ФАРМАЦЕУТСКО-ТЕХНОЛОШКЕ ФОРМУЛАЦИЈЕ ТАБЛЕТА ЛАМОТРИГИНА СА ТРЕНУТНИМ ОСЛОБАЂАЊЕМ | | | | Гордана Швоња Парезановић | | | | 2016.  (истекао рок за одбрану) | |  | |
| 2. | ОДРЕЂИВАЊЕ ФАРМАКОКИНЕТИКЕ МЕТОТРЕКСАТА У ЕКСПЕРИМЕНТАЛНОМ МОДЕЛУ ПРИМЕНОМ СУВЕ КАПИ КРВИ | | | | Ивана Рајшић | | | | 2019. | |  | |
| 3. | УТИЦАЈ ЖУЧНИХ КИСЕЛИНА НА БИОРАСПОЛОЖИВОСТ МАКРОЛИДНИХ АНТИБИОТИКА | | | | Јована Трифуновић | | | |  | | 2016. | |
| 4. | БИОХЕМИЈСКА И ХЕМИЈСКА КАРАКТЕРИЗАЦИЈА ЕКСТРАКАТА БОСИЉКА И УТИЦАЈ ФАРМАЦЕУТСКО-ТЕХНОЛОШКЕ ФОРМУЛАЦИЈЕ НА ГЛИКЕМИЈСКИ, ЛИПИДНИ И ОКСИДО-РЕДУКЦИОНИ СТАТУС КОД ОГЛЕДНИХ ЖИВОТИЊА | | | | Бранислава Теофиловић | | | |  | | 2017. | |
| 5. | УТИЦАЈ ФАРМАЦЕУТСКО-ТЕХНОЛОШКЕ ФОРМУЛАЦИЈЕ У ОБЛИКУ МИКРОВЕЗИКУЛА СА АЛГИНАТОМ НА РЕСОРПЦИЈУ ГЛИКЛАЗИДА ИЗ ДИГЕСТИВНОГ ТРАКТА ПАЦОВА | | | | Јелена Ћаласан | | | |  | | 2019. | |
| \*Година у којој је дисертација-докторски уметнички пројекат пријављена-пријављен (само за дисертације-докторске уметничке пројекте које су у току), \*\* Година у којој је дисертација-докторски уметнички пројекат одбрањена (само за дисертације-докторско уметничке пројекте из ранијег периода) | | | | | | | | | | | | |
| **Категоризација публикације научних радова из области датог студијског програма према класификацији ресорног Министарства просвете, науке и технолошког развоја а у складу са допунским захтевевима стандарда за дато поље** | | | | | | | | | | | | |
| Р.б. | Публикација | | | | | | | ISI | | M | | IF |
|  | Pavlović N, Milošević N, Đanić M, **Goločorbin-Kon S**, Stanimirov B, Stankov K, Mikov M. Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: A Pharmacoinformatic Preliminary Study. Anticancer Agents Med Chem. 2022;22(7):1407-13. [doi.org/](https://doi.org/10.3390/gels8010035)[[10.2174/1871520621666210608102452](https://doi.org/10.3390/gels8010035)](https://doi.org/10.2174/1871520621666210608102452) | | | | | | | 46/63  (2021) | | 23 (2021) | | 2.527  (2021) |
|  | Pavlović N, Bogićević I, Zaklan D, Djanić M, **Goločorbin-Kon** S, Al-Salami H, Mikov M. [Influence of bile acids in hydrogel pharmaceutical formulations on dissolution rate and permeation of clindamycin hydrochloride](https://mdpi-res.com/d_attachment/gels/gels-08-00035/article_deploy/gels-08-00035.pdf). Gels. 2022;8(1):35. | | | | | | | 22/90  (2021) | | 21 (2021) | | 4.432  (2021) |
|  | Rajsic I, Lazarevic S, Djanic M, Al-Salami H, Mooranian A, Vukmirovic SN, Mikov M, **Goločorbin-Kon S**. Plasma distribution of Methotrexate and its polyglutamates in pediatric acute lymphoblastic leukemia: Preliminary Insights. Eur J Drug Metab Pharmacokinet. 2022;47(1):127-34. doi: 10.1007/s13318-021-00726-9 | | | | | | | 200/279 (2021) | | 23 (2021) | | 2.569 (2021) |
|  | Teofilović BD, **Goločorbin-Kon S**, Stilinović N, Grujić-Letić N, Rašković A, Mooranian A, et al ... Mikov M. [Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study](https://www.nature.com/articles/s41598-021-01713-5.pdf). Sci Rep. 2021;11(1):22123. | | | | | | | 19/73 | | 21 | | 4.996 |
|  | Rajsic I, Pavlovic N, Milijasevic B, Vukmirovic S, Spasic DT, Zigic M, Grahovac N, **Goločorbin-Kon S,** et al. [The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection](http://www.doiserbia.nb.rs/img/doi/0042-8450/2021/0042-84501900126R.pdf). Vojnosanit Pregl. 2021;78(7):708-15. | | | | | | | 168/172 | | 23 | | 0.245 |
|  | Jovičić-Bata J, Pavlović N, Milošević N, Gavarić N, **Goločorbin-Kon** S, Todorović N, Lalić-Popović M. [Coping with the burden of the COVID-19 pandemic: a cross-sectional study of community pharmacists from Serbia](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022120/pdf/12913_2021_Article_6327.pdf). BMC Health Serv Res. 2021 Apr 6;21(1):304. | | | | | | | 63/109 | | 22 | | 2.908 |
|  | Kecman S, Škrbić R, Badnjević-Čengić A, Mooranian A, Al-Salami H, Mikov M, **Goločorbin-Kon S**. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. Technol Health Care. 2020;28:3:325-35. | | | | | | | 102/109 | | 23 | | 1.285 |
|  | Wagle S, Walker D, Kovačević B, Gedway A, Mikov M, **Goločorbin-Kon S**, Mooranian A, Al-Salami H[. Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies](https://ezproxy.nb.rs:2171/articles/s41598-020-64355-z.pdf). Sci Rep. 2020;10:7715. | | | | | | | 17/73 | | 21 | | 4.379 |
|  | Maksimović V, Pavlović-Popović Z, Vukmirović S, Cvejić J, Mooranian A, Al-Salami H, Mikov M, **Goločorbin-Kon S**. [Molecular mechanism of action and pharmacokinetic properties of metotrexate](https://ezproxy.nb.rs:2078/content/pdf/10.1007/s11033-020-05481-9.pdf). Mol Biol Rep. 2020;47:4699-708. | | | | | | | 239/297 | | 23 | | 2.316 |
|  | Mooranian A, Zamani N, Ionescu C, Takechi R, Luna G, Mikov M, **Goločorbin-Kon S**, Kovačević B, Al-Salami. Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflamation. Pharmacol Rep. 2020;72(2):368-78. | | | | | | | 163/275 | | 22 | | 3.024 |
|  | Mooranian A, Wagle S, Kovačević B, Takechi R, Mamo J, Lam V, Watts G, Mikov M, **Goločorbin-Kon S**, Stojanović G, Al-Salami H, Al-Salami H. [Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study](https://ezproxy.nb.rs:2171/articles/s41598-019-53999-1.pdf). Sci Rep. 2020;10:106. | | | | | | | 17/73 | | 21 | | 4.379 |
|  | [Paut-Kusturica M,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Paut-Kusturica%20Milica%20M)[**Golocorbin-Kon S**,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Golocorbin-Kon%20Svetlana) [Ostojic T,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Ostojic%20Tijana)[Kresoja M,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Kresoja%20Milena%20S)[Milovic M,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Milovic%20Marko%20J)[Horvat O,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Horvat%20Olga%20J)[Dugandzija T,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Dugandzija%20Tihomir)[Davidovac N,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Davidovac%20Nada)[Vasic A,](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Vasic%20Anica)[Tomas A.](https://ezproxy.nb.rs:2443/nauka_u_srbiji.132.html?autor=Tomas%20Ana%20D)[Consumer willingness to pay for a pharmaceutical disposal program in Serbia: A double hurdle modeling approach](https://pdf.sciencedirectassets.com/271837/1-s2.0-S0956053X20X0002X/1-s2.0-S0956053X20300374/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEF8aCXVzLWVhc3QtMSJHMEUCIHBJgt1MthxXUoC5gdKX6Jmqfgd%2FC36DnfX8Cl0I2RhtAiEAyl9iwvXXo%2B%2B%2FfkJHJIEWp2h7ujDNSgAevxOzX). Waste Manag. 2020;104:246-53. | | | | | | | 10/54 | | 21 | | 7.145 |
|  | Parezanović-Švonja G, Lalić-Popović M, **Goločorbin-Kon S**, Todorović N, Pavlović N, Mikov M. [In vitro comparative quality evaluation of non-expired and ten years expired lamotrigine immediate-release tablet formulations - pilot study.](http://dissolutiontech.com/issues/202002/DT202002_A02.pdf) Dissolut Technol. 2020;27:14-20. | | | | | | | 258/275 | | 23 | | 0.978 |
|  | Mikov M, Pavlović N, Stanimirov B, Djanić M, **Goločorbin-Kon S**, Stankov K, Al-Salami H. DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment. Eur J Drug Metab Pharmakokinet. 2020;45(1):1-14. | | | | | | | 201/275 | | 23 | | 2.441 |
|  | Mooranian A, Zamani N, Mikov M, **Goločorbin-Kon S**, Stojanović G, Arfuso F, Kovačević B, Al-Salami H. [A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds](https://pdf.sciencedirectassets.com/278665/1-s2.0-S1319016420X00028/1-s2.0-S1319016419301689/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEF4aCXVzLWVhc3QtMSJGMEQCICkM4xOwHmx8ZICfRyvUjdWnmSaz0yn32XYSdV%2FqeJwgAiBFtW5gTBlMWGTHqwHoMjWUHa%2BL9AeUH6n5RTQirJ4P3). Saudi Pharm J. 2020;28(2):165-71. | | | | | | | 65/267  (2018) | | 21 (2018) | | 3.643  (2018) |
|  | Bjelica A, Aleksić S, **Goločorbin-Kon S**, Sazdanić D, Torović Lj, Cvejić J[. Internet marketing of cardioprotective dietary supplements](https://www.liebertpub.com/doi/pdf/10.1089/acm.2019.0128). J Altern Complement Med. 2020;26(3):204-11. | | | | | | | 13/29 | | 22 | | 2.579 |
|  | Pavlović N, Djanić M, Stanimirov B, **Goločorbin-Kon S**, Stankov K, Lalić-Popović M, Mikov M. In silico discovery of resveratrol analogues as potential agents in treatment of metabolic disorders. Curr Pharm Design. 2019;35:3776-83. | | | | | | | 148/267  (2018) | | 22 (2018) | | 2.412  (2018) |
|  | Mooranian A, Zamani N, Luna G, Al-Sallami H,Mikov M, **Goločorbin-Kon S**, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H. [Bile acid-polymer-probucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model.](https://pubmed.ncbi.nlm.nih.gov/31557068/) Pharm Dev Technol. 2019; 24(10):1272-77. | | | | | | | 153/267 (2018) | | 22 (2018) | | 2.347 (2018) |
|  | Lazarević S, Đanić M, **Goločorbin-Kon S**, Al-Salami H, Mikov M. [Semisynthetic bile acids: a new therapeutic option for metabolic syndrome](https://reader.elsevier.com/reader/sd/pii/S1043661819302786?token=0AA8487A42CEA9758CB784474CA8FA375A9427BB87B26AA330039E91DD52AFB11273FBB008F7DA3463F84C0CA852B5C0). Pharmacol Res. 2019;146:104333. | | | | | | | 19/270 | | 21a | | 5.893 |
|  | Parezanović GŠ, Lalic-Popovic M, **Golocorbin-Kon S**, Vasovic V, Milijašević B, Al-Salami H, Mikov M. [Environmental transformation of pharmaceutical formulations: a scientific review](https://link.springer.com/content/pdf/10.1007%2Fs00244-019-00630-z.pdf). Arch Environ Contam Toxicol. 2019;77(2):151-61. | | | | | | | 133/265 | | 22 | | 2.400 |
|  | Mooranian A, Zamani N, Takechi R, Luna G, Mikov M, **Goločorbin-Kon S**, Elnashar M, Arfuso F, Al-Salami H. [An in vivo pharmacological study: variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449070/pdf/pone.0214984.pdf). PLoS ONE. 2019;14(4):e0214984. | | | | | | | 15/64  (2017) | | 21  (2017) | | 2.766  (2017) |
|  | Mooranian A, Zamani N, Takechi R, Al-Sallami H, Mikov M, **Goločorbin-Kon S**, Kovacevic B, Arfuso F, Al-Salami H. [Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes](https://www.tandfonline.com/doi/pdf/10.1080/21691401.2018.1511572). Artif Cells Nanomed Biotechnol. 2018;46(sup3):S748-54. | | | | | | | 3/33  (2016) | | 21a  (2016) | | 5.605  (2016) |
|  | Mooranian A, Zamani N, Mikov M, **Goločorbin-Kon S**, Stojanovic G, Arfuso F, Al-Salami H. [Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses](https://www.tandfonline.com/doi/pdf/10.1080/21691401.2018.1511571?needAccess=true). Artif Cells Nanomed Biotechnol. 2018;46(sup3):S741-7. | | | | | | | 3/33  (2016) | | 21a  (2016) | | 5.605  (2016) |
|  | **Goločorbin-Kon S**, Mikov M, Cvejić-Hogervorst JM, Al-Salami H, Maksimović V[. Dried blood spot: utilising dry blood for pharmacokinetic investigations - an old method with great future for therapeutic drug monitoring](http://www.doiserbia.nb.rs/img/doi/0042-8450/2018/0042-84501700046G.pdf). Vojnosanit Pregl. 2018;75(12):1222-5. | | | | | | | 155/160 | | 23 | | 0.272 |
|  | Ðanić M, Stanimirov B, Pavlović N, **Goločorbin-Kon S**, Al-Salami H, Stankov K, Mikov M. [Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome](https://www.frontiersin.org/articles/10.3389/fphar.2018.01382/full). Front Pharmacol. 2018;9:1382. | | | | | | | 59/267 | | 21 | | 3.845 |
|  | Pavlović N, **Goločorbin-Kon S**, Ðanić M, Stanimirov B, Al-Salami H, Stankov K, Mikov M. [Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles](https://www.frontiersin.org/articles/10.3389/fphar.2018.01283/full). Front Pharmacol. 2018;9:1283. | | | | | | | 59/267 | | 21 | | 3.845 |
|  | Mikov M, Đanić M, Pavlović N, Stanimirov B, **Goločorbin-Kon S**, Stankov K, Al-Salami H. [Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics](https://link.springer.com/article/10.1007%2Fs13318-017-0441-y). Eur J Drug Metab Pharmacokinet. 2018;43(3):269-80. | | | | | | | 221/267 | | 23 | | 1.497 |
|  | Mathavan S, Mikov M, **Goločorbin-Kon S**, Al-Salami H. [Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects](https://ac.els-cdn.com/S0928098717302695/1-s2.0-S0928098717302695-main.pdf?_tid=33e083c2-ce9d-11e7-8461-00000aab0f6c&acdnat=1511256203_cac717e2567fa55379e962c72dfcaadf). Eur J Pharm Sci. 2017;106:1-9. | | | | | | | 68/261 | | 21 | | 3.466 |
|  | Mikov M, Đanić M, Pavlović N, Stanimirov B, **Goločorbin-Kon S**, Stankov K, Al-Salami H. [The role of drug metabolites in the inhibition of cytochrome P450 Enzymes](https://link.springer.com/article/10.1007%2Fs13318-017-0417-y). Eur J Drug Metab Pharmacokinet. 2017;42(6):881-90. | | | | | | | 221/261 | | 23 | | 1.362 |
|  | **Goločorbin-Kon S**, Calasan J, Milijasevic B, Vukmirovic S, Lalic-Popovic M, Mikov M, Al-Salami H. [High-loading dose of microencapsulated gliclazide formulation exerted a hypoglycaemic effect on type 1 diabetic rats and incorporation of a primary deconjugated bile acid, diminished the hypoglycaemic antidiabetic effect](https://link.springer.com/content/pdf/10.1007%2Fs13318-017-0415-0.pdf). Eur J Drug Metab Pharmacokinet. 2017;42(6):1005-11. | | | | | | | 221/261 | | 23 | | 1.362) |
|  | [Teofilovic B,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Teofilovic%20Branislava) [Grujic-Letic N,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Grujic-Letic%20Nevena%20N) [**Golocorbin-Kon S,**](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Golocorbin-Kon%20Svetlana) [Stojanovic S,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Stojanovic%20Srdjan) [Vastag G,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Vastag%20Gyongyi%20Dj) [Gadzuric S.](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Gadzuric%20Slobodan%20B) [Experimental and chemometric study of antioxidant capacity of basil (Ocimum basilicum) extracts](http://ac.els-cdn.com/S0926669017301425/1-s2.0-S0926669017301425-main.pdf?_tid=03f3e674-5808-11e7-94cd-00000aab0f01&acdnat=1498217890_06908677b16e50a74edcac4c818cc115). Ind Crops Prod. 2017;100:176-82. | | | | | | | 6/87 | | 21a | | 3.849 |
|  | [Lalic-Popovic M,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Lalic-Popovic%20Mladena) [Paunkovic J,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Paunkovic%20Jovana) [Grujic Z,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Grujic%20Zorica) [**Golocorbin-Kon S,**](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Golocorbin-Kon%20Svetlana) [Vasovic V,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Vasovic%20Velibor%20M) [Al-Salami H,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Al-Salami%20Hani) [Mikov M.](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Mikov%20Momir%20M) [The effect of diabetes and hypertension on the placental permeation of the hydrophilic drug, ranitidine](http://ac.els-cdn.com/S0143400416305926/1-s2.0-S0143400416305926-main.pdf?_tid=8a5e73dc-5808-11e7-927d-00000aab0f02&acdnat=1498218116_940e5e8f53803f42e2ca2ac04a1f6b3c). Placenta. 2016;48:144-50. | | | | | | | 19/80 | | 21 | | 2.759 |
|  | Trifunović J, Borčić V, Vukmirović S, Mikov M, **Goločorbin-Kon S**. [Retention data of bile acids and their oxo derivates in characterization of pharmacokinetic properties and in silico ADME modeling](http://ac.els-cdn.com/S0928098716302652/1-s2.0-S0928098716302652-main.pdf?_tid=c5b28a98-5a3a-11e7-a52a-00000aab0f02&acdnat=1498459593_d4142cd0e3a72b1f0fcfb02005c19731). Eur J Pharm Sci. 2016;92:194-202. | | | | | | | 54/256 | | 21 | | 3.756 |
|  | Suvajdžić Lj, Gigov S, Rašković A, Stojanović S, Bekut A, Milanov D, Čanak I, **Golocorbin-Kon S**, Mikov M. [Influence of the sodium salt of 3a,7a-dihydroxy-12-oxo-5-cholanate on antimicrobial activity of ampicillin in vitro](http://www.ufrgs.br/actavet/44/PUB%201397.pdf). Acta Sci Vet. 2016;44(1397): 1-6. | | | | | | | 119/136 | | 23 | | 0.234 |
|  | Djanic M, Pavlovic N, Stanimirov B, Stojancevic T, **Golocorbin-Kon S**, Bojic G, Mikov M. [Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria](https://www.researchgate.net/profile/Maja_Danic_stojancevic/publication/295909947_Docking-based_preliminary_study_on_the_interactions_of_bile_acids_with_drugs_at_the_transporter_level_in_intestinal_bacteria/links/56d4376a08ae2ea08cf8e1d2/Docking-based-prel). Eur Rev Med Pharmacol Sci. 2016;20(3):553-60. | | | | | | | 180/256 | | 23 | | 1.778 |
|  | Lalic-Popovic M, Paunkovic J, Grujic Z, **Golocorbin-Kon S**, Milasinovic Lj, Al-Salami H, Mikov M. [Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes](http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12288/pdf). [J Diabetes.](http://www.ncbi.nlm.nih.gov/pubmed/25800069" \o "Journal of diabetes.) 2016;8(2):238-45. | | | | | | | 70/138 | | 22 | | 3.039 |
|  | Negrulj R, Mooranian A, Chen-Tan N, Al-Sallami HS, Mikov M, **Golocorbin-Kon S**, Fakhoury M, Watts GF, Arfuso F, Al-Salami H. [Swelling, mechanical strenght, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes](https://ezproxy.nb.rs:2201/doi/pdf/10.3109/21691401.2015.1024845?needAccess=true). Artif Cells Nanomed Biotechnol. 2016;44(5):1290-7. | | | | | | | 4/77 | | 21a | | 5.605 |
|  | Mooranian A, Negrulj R, Mikov M, **Golocorbin-Kon S**, Arfuso F, Al-Sallami H. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study. J Microencapsul. 2015;32(6):589-97. | | | | | | | 31/72 | | 22 | | 1.631 |
|  | Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, **Golocorbin-Kon S**, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151-6. | | | | | | | 31/72 | | 22 | | 1.631 |
|  | Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciaretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalić-Popović M, Stojancevic M, **Golocorbin-Kon S**, Al-Sallami H. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015;20(6):702-9. | | | | | | | 188/255 | | 23 | | 1.566 |
|  | Mooranian A, Negrulj R, Al-Sallami HS, Fang ZX, Mikov M**, Golocorbin-Kon S**, et al. [Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes](https://link.springer.com/content/pdf/10.1208%2Fs12249-014-0205-9.pdf). AAPS PharmSciTech 2015;16(1):45-52. | | | | | | | 159/255 | | 23 | | 1.954 |
|  | Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, Mikov M, **Golocorbin-Kon S**, et al. [Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol](https://www.dovepress.com/microencapsulation-as-a-novel-delivery-method-for-the-potential-antidi-peer-reviewed-fulltext-article-DDDT). Drug Des Devel Ther. 2014;8:1221-30. | | | | | | | 17/59 | | 21 | | 3.028 |
|  | Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, Mikov M, **Golocorbin-Kon S**, et al. [Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characerization study](https://www.dovepress.com/novel-artificial-cell-microencapsulation-of-a-complex-gliclazide-deoxy-peer-reviewed-fulltext-article-DDDT). Drug Des Devel Ther. 2014;8:1003-12. | | | | | | | 17/59 | | 21 | | 3.028 |
|  | Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur T, Mikov M, Lalic-Popovic M, Stojancevic M, **Golocorbin-Kon S**, Al-Salami H. [Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics](https://link.springer.com/content/pdf/10.1007%2Fs12247-014-9182-5.pdf). J Pharm Innov. 2014;9(2):150-7. | | | | | | | 218/255 | | 23 | | 1.000 |
|  | Raskovic A, Cvejic J, Stilinovic N, **Golocorbin-Kon S**, Vukmirovic S, Mimica-Dukic N, Mikov M. [Interaction between different extracts of hypericum perforatum L. From Serbia and pentobarbital, diazepam and paracetamol](http://www.mdpi.com/1420-3049/19/4/3869). Molecules. 2014;19:3869-82. | | | | | | | 22/58 | | 22 | | 2.416 |
|  | Milic N, Milosevic N, **Golocorbin-Kon S**, Bozic T, Abenavoli L, Borelli F. [Warfarin interactions with medicinal herbs](https://www.researchgate.net/publication/265651691_Warfarin_Interactions_with_Medicinal_Herbs). Nat Prod Commun. 2014;9(8):1211-6. | | | | | | | 69/124  (2012) | | 22  (2012) | | 0.956  (2012) |
|  | Stojančević M, Pavlović N, **Goločorbin-Kon S**, Mikov M. Application [of bile acids in drug formulation and delivery](http://www.tandfonline.com/doi/full/10.1080/21553769.2013.879925?scroll=top&needAccess=true). HFSP J. 2013;7(3-4):112-22. | | | | | | | 48/55 | | 23 | | 0.227 |
|  | **Lalic-Popovic М, Paunkovic Ј, Grujic Z, Golocorbin-Kon S, Al-Salami H, Mikov M.** [Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women](https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/1471-2393-13-188). BMC Pregnancy Childbirth. 2013;1**3(**188). doi:10.1186/1471-2393-13-188 | | | | | | | 39/199  (2012) | | 21  (2012) | | 2.516  (2012) |
|  | Lalić-Popović M, Vasović V, Milijašević B, **Goločorbin-Kon S**, Al-Salami H, Mikov M. [Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat](https://www.hindawi.com/journals/jdr/2013/598603/). J Diabetes Res. 2013;2013:1-8.  *Napomena*: prethodni naslov časopisa Experimental Diabetes Research | | | | | | | 123/124 | | 23 | | 0.000 |
|  | Mikov I, Stankov K, Vasovic V, Mikov A, **Golocorbin – Kon S**, Mikov M. [Effects of simultaneous exposure to benzene and ethanol on urinary thioesters excretion](http://archiwum.ciop.pl/50499). Int J Occup Saf Ergon. 2012;18(1):107-11. | | | | | | | 218/239 | | 23 | | 0.494 |
|  | Pavlović N, Stanimirov B, Stojančević M, Paut- Kusturica M, Stoimenova A, **Goločorbin-Kon S**, Mikov M. [An Insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden](http://www.tandfonline.com/doi/pdf/10.5504/BBEQ.2012.0085?needAccess=true). Biotechnol Biotec Eq. 2012;26(5):3236-41. | | | | | | | 137/160 | | 23 | | 0.622 |
|  | Oana M, [Simona MD,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Simona%20Miron%20Dalia) [Dumitru L,](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Lupuleasa%20Dumitru)Adriana MM, [**Golocorbin-Kon S,**](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Golocorbin-Kon%20Svetlana) [Stefan RF](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Radulescu%20Flavian%20Stefan). The Influence of Structural Characteristics on the in vitro drug release rate of terbinafine from topical gels. Farmacia. 2012;60(3):325-33. | | | | | | | 230/261 | | 23 | | 0.578 |
|  | [Al-Salami H](http://www.scopus.com.proxy.kobson.nb.rs:2048/authid/detail.url?origin=resultslist&authorId=24330693200&zone=), [Butt G](http://www.scopus.com.proxy.kobson.nb.rs:2048/authid/detail.url?origin=resultslist&authorId=36112981600&zone=), [Tucker I](http://www.scopus.com.proxy.kobson.nb.rs:2048/authid/detail.url?origin=resultslist&authorId=7005479467&zone=), [**Goločorbin-Kon S**](http://www.scopus.com.proxy.kobson.nb.rs:2048/authid/detail.url?origin=resultslist&authorId=24766016900&zone=)**,** [Mikov M](http://www.scopus.com.proxy.kobson.nb.rs:2048/authid/detail.url?origin=resultslist&authorId=7004445539&zone=). [Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats](https://link.springer.com/content/pdf/10.1007%2Fs13318-011-0060-y.pdf). Eur J Drug Metab Ph. 2012;37(2):99-108. | | | | | | | 213/261 | | 23 | | 0.944 |
| **Збирни подаци научне активност наставника** | | | | | | | | | | | | |
| **Збирни подаци уметничке активност наставника** | | | | | | | | | | | | |
| Укупан број цитата, без аутоцитата | | | | 1169 | | | | | | | | |
| Укупан број радова са SCI (или SSCI) листе | | | | 60 | | | | | | | | |
| Тренутно учешће на пројектима | | | | Домаћи: 2 | | Међународни: 1 | | | | | | |
| Усавршавања | | | | 1. Отаго Универзитет, Фармацеутски факултет, Дунедин, Нови Зеланд (School of Pharmacy, Otago University, New Zealand) (2004-2008) 2. Фармацеутски факултет у Перту, Куртин Универзитет (School of Pharmacy, Curtin University, Perth, Western Australia) 22. 6 - 21. 7 2013. 3. Генохем (Genohem), Грассе, Фрaнцуска. (23. 9 - 25.10 2016.) 4. Фармацеутски факултет у Перту, Куртин Универзитет (School of Pharmacy, Curtin University, Perth. Western Australia) 17.11. 2017. - 18.2. 2018. 5. Краљевски Сонгкла Универзитет Хат Јаи, Тајланд, (Prince of Songkla University, Hat Yai), 24.7. 2018.- 23.8. 2018. у оквиру МEDLEM пројекта HORIZON 2020 6. Универзитет у Мунстеру – компанија Маркотех у Немачкој (University of Munster, Nemačka- company Marcotech) od 28.3.2019. do 31.3.2019. у оквиру МEDLEM пројекта HORIZON 2020 | | | | | | | | |
| Други подаци које сматрате релевантним | | | | 1. Члан уређивачког одбора Flogiston-a, часописа за историју науке, који издаје Музеј науке и технике Београд, ISSN 035-6640 oд 2015 године. 2. Награда Медицинског факултета, Универзитета у Новом Саду за изузетне резултате постигнуте у извођењу наставе, 2016 3. Почасни члан Фармацеутске коморе Србије, 2017 4. Награда Медицинског факултета, Универзитета у Новом Саду за изузетне резултате постигнуте у извођењу наставе, 2018 | | | | | | | | |